Added to YB: 2026-04-14
Pitch date: 2026-04-10
GSK [neutral]
GSK plc
+0.88%
current return
Author Info
No bio for this author
Company Info
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally.
Market Cap
GBP 87.0B
Pitch Price
GBP 21.51
Price Target
N/A
Dividend
3.31%
EV/EBITDA
8.74
P/E
15.68
EV/Sales
3.09
Sector
Pharmaceuticals
Category
growth
Theodosian Capital | Stocks Update 10/4/2026 - GSK – Pipeline progress
GSK (update): Depemokimab approved in China for CRSwNP - first & only ultra-long-acting biologic approved there. Already approved for CRSwNP & severe asthma in EU/UK/Japan, severe asthma in US. Pipeline advancing. Trades 11.3x FY27 EPS, 3.4% yield.
Read full article (1 min)